FTC clears Mylan merger with Pfizer’s Upjohn – with conditio...

Mylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the condition that the two companies divest various generic drug products.

FDA’s review date for BMS’ ide-cel sneaks under the CVR wire

The FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel, just in time to meet a contingent value right (CVR) due to Celgene shareholde

Saunders steps aside as AbbVie closes in on Allergan merger

Lawmaker weighs in on Gottlieb switch to industry

eRegulatory Summit

Telematics, RIM, eCTD, IDMP and Filing Variations

Explore New Strategies to Maintain a Global Pharmacovigilanc...

Drug Safety 2018